To get therapies into the brain after a stroke, researchers are increasingly making use of the blood-brain barrier, which allows only certain molecules to pass from the blood into the brain. In a study published earlier this year in Molecular Therapy, Japanese researchers have found that antisense oligonucleotides — specialized molecules that can modulate RNA and alter protein production — are preferentially taken up from the blood into areas of stroke damage when they’re linked to a specific kind of lipid known as ?-tocopherol (TOC).

Current stroke therapies are only effective if they are delivered within a short window of time, which limits their effectiveness in many patients. Many new therapies are being investigated that can be applied outside this short window of opportunity. One such therapy involves the use of antisense oligonucleotides, which can be targeted to increase the production of beneficial proteins after a stroke, for example, or to decrease the production of harmful proteins. However, getting these molecules into the right area at the right time can be difficult, something that the researchers at Tokyo Medical and Dental University wanted to address.

“We’ve recently developed an antisense oligonucleotide known as a DNA/RNA heteroduplex oligonucleotide, or HDO,” says senior author of the study Takanori Yokota. “To see how different lipids affect the uptake of HDO in the brain, we linked it to either cholesterol or TOC and then injected it into the blood of mice who had been given an experimentally induced stroke in just one side of the brain.”

Unexpectedly, the TOC-linked molecules were observed at very high levels in the stroke-lesioned side of the brain only, whereas the cholesterol-linked molecules were high in both sides of the brain. This suggests that TOC specifically increases HDO uptake after stroke, while cholesterol does not. Furthermore, because HDO can be tailored to target different genes, it was used to silence a gene known to be beneficial in stroke. As expected, the researchers observed greater areas of stroke-related damage in the mice treated with this TOC-linked HDO.

“Together, our findings suggest that TOC-linked HDO is safe to use and is preferentially taken up and incorporated into cells in areas of stroke damage,” says Yokota. “This delivery method is potentially very useful for the targeted up- or down-regulation of protein expression after stroke.”

Given the relative lack of stroke therapies targeting the pathological processes that happen after a stroke, the current findings are very important. Increasing anti-inflammatory proteins and/or lowering inflammatory proteins in the stroke-lesioned brain is a promising way to avoid secondary damage to the brain after a stroke has occurred, and will lead to reductions in stroke-related disabilities.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

what is 2 plus 5?

Explore More

New bone conduction implant approved in Europe and US

Sentio bone conduction implant. Credit: Oticon Medical After over two decades of intensive research and development, a new bone conduction implant, the Sentio System, has now been approved for clinical

Prostate cancer symptoms and treatment: What to check for

There is no single, diagnostic test. Doctors make a diagnosis based on various measures. This can include a prostate-specific antigen (PSA) blood test and a scan, as well as a

New CAR T-Cell therapy extends remission in heavily relapsed multiple myeloma patients

A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial